{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:58Z","timestamp":1793214658022,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-EY06360"],"award-info":[{"award-number":["P30-EY06360"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ophtha.2020.01.006","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T11:39:33Z","timestamp":1578656373000},"page":"948-955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":188,"title":["Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis"],"prefix":"10.1016","volume":"127","author":[{"given":"Steven","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul N.","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Kissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ophtha.2020.01.006_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/aos.14042","article-title":"Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach","volume":"97","author":"Habot-Wilner","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.01.006_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2015.02.021","article-title":"Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model","volume":"203","author":"Chen","year":"2015","journal-title":"J\u00a0Control Release"},{"issue":"9","key":"10.1016\/j.ophtha.2020.01.006_bib3","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"Durrani","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"5\u20136","key":"10.1016\/j.ophtha.2020.01.006_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF00163549","article-title":"The natural history of uveitis","volume":"14","author":"Nussenblatt","year":"1990","journal-title":"Int Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2020.01.006_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2020.01.006_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3341\/kjo.2012.26.5.362","article-title":"A\u00a0three-year follow-up of intravitreal triamcinolone acetonide injection and macular laser photocoagulation for diffuse diabetic macular edema","volume":"26","author":"Cho","year":"2012","journal-title":"Korean J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ophtha.2020.01.006_bib7","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.ophtha.2015.06.042","volume":"122","author":"Multicenter Uveitis Steroid Treatment Trial Research Group","year":"2015","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ophtha.2020.01.006_bib8","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial","volume":"118","author":"Multicenter Uveitis Steroid Treatment Trial Research Group","year":"2011","journal-title":"Ophthalmology"},{"issue":"19","key":"10.1016\/j.ophtha.2020.01.006_bib9","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis","volume":"317","author":"Writing Committee for the Multicenter Uveitis Steroid Treatment Trial","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ophtha.2020.01.006_bib10","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1097\/IAE.0000000000000726","article-title":"Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations","volume":"35","author":"Yang","year":"2015","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ophtha.2020.01.006_bib11","first-page":"835","article-title":"Results of intravitreal dexamethasone implant 0.7 mg (Ozurdex(R)) in non-infectious posterior uveitis","volume":"8","author":"Yap","year":"2015","journal-title":"Int J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ophtha.2020.01.006_bib12","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ophtha.2014.05.021","article-title":"Periocular corticosteroid injections in uveitis: effects and complications","volume":"121","author":"Sen","year":"2014","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2020.01.006_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/jop.2006.0067","article-title":"The etiology of steroid cataract","volume":"23","author":"James","year":"2007","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2020.01.006_bib14","first-page":"125","article-title":"Gene expression profile of human trabecular meshwork cells in response to long-term dexamethasone exposure","volume":"12","author":"Rozsa","year":"2006","journal-title":"Mol Vis"},{"issue":"3","key":"10.1016\/j.ophtha.2020.01.006_bib15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2020.01.006_bib16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ajo.2011.05.028","article-title":"Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography","volume":"152","author":"Sugar","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2020.01.006_bib17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2013.09.023","article-title":"Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema","volume":"121","author":"Levin","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2020.01.006_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.01.006_bib19","series-title":"Alcon Laboratories, Inc. Triesence [package insert]","year":"2007"},{"issue":"2","key":"10.1016\/j.ophtha.2020.01.006_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017140","article-title":"Ab-externo AAV-mediated gene delivery to the suprachoroidal space using a 250 micron flexible microcatheter","volume":"6","author":"Peden","year":"2011","journal-title":"PLoS One"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020300117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020300117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:08:37Z","timestamp":1758982117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642020300117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0161642020300117"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.01.006","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738233732.793589539","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}